Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Deals Shrink, Indian Companies Ask MNCs To Stay Open For Drug Discovery Partnerships - PharmAsia Summit

This article was originally published in PharmAsia News

Executive Summary

SAN FRANCISCO - Consolidation among Big Pharma has resulted in fewer opportunities for smaller companies to out-license newly researched compounds, while the inclination of large companies to selectively work only on "first-to-market" drugs has complicated deal-making for companies with early-stage leads

You may also be interested in...



Advinus Moves Ahead With Anti-Diabetes Lead As Tata Group Looks For Strategic Allies

The Indian venture is exploring financing options even as its lead molecule shows promise.

Asia Spotlight Preview: BCG Study Of India R&D Suggests Leveraging Of "Niche Busters” And Stem Cells

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

Asia Spotlight Preview: BCG Study Of India R&D Suggests Leveraging Of "Niche Busters” And Stem Cells

On the second Monday of each month, "The Pink Sheet" provides exclusive news and commentary on the Asia biopharma market from the editors of its affiliated online publication, PharmAsia News. Register at http://pharmasianews.elsevierbi.com/PAN_Trial_LP.html for a free trial.

Related Content

Latest News
See All
UsernamePublicRestriction

Register

SC073583

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel